Vincent L. Capuano

Vincent L. Capuano — patent litigation summary

Specialty / focus. Capuano's practice is concentrated in chemistry and life sciences — small-molecule pharmaceuticals, generics and biosimilars, ANDA/Hatch-Waxman work, biotech, cannabis-related IP, and medical devices/delivery devices — rather than software or communications standards. He holds a Ph.D. in organic chemistry (University of Texas at Austin, 1991) and worked as an organic chemist and postdoctoral fellow before law school, and his practice descriptions emphasize patent procurement, validity/infringement analysis, licensing and due diligence alongside litigation, plus trade-secret work in the pharma and cannabis spaces. His single tracked appearance fits that profile: Albaugh, LLC v. BASF SE, an agrochemical/herbicide dispute over L-glufosinate formulations, in which he is lead counsel for plaintiff Albaugh.

Side preference. On the tracked data he is 1-for-1 on the plaintiff/challenger side, but the better reading of his career is that he primarily represents generic, biosimilar and challenger companies against brand-holder patents — a posture that shows up as either defense in ANDA suits or as affirmative patent-office challenges. That is consistent with the Albaugh matter, where Albaugh is the party attacking a branded agrochemical patent. There is no indication in the tracked data or public sources that he works the NPE/PAE plaintiff side; his client base has been operating companies.

Firm context. Capuano founded Capuano IP (Salem, Massachusetts) in 2020, described as a micro-boutique focused on chemistry, pharmaceutical and related life-sciences IP and litigation, and he appears as Capuano IP counsel on the 2026 Albaugh PTAB filing. Before that he spent roughly a decade as a partner in the Boston office of Duane Morris LLP (from 2008), and before that was an associate/director at Sterne, Kessler, Goldstein & Fox (1998–2008) and a patent agent/law clerk at Oldham & Oldham (1996–1998). Note that several third-party directory profiles still list Duane Morris as his current firm, which appears to be stale.

Notable matters / PTAB / bar. Public firm profiles list him on generic-side pharmaceutical matters including Bristol-Myers Squibb v. Prinston (Eliquis/apixaban), Helsinn v. Actavis (Aloxi/palonosetron), Bayer v. Prinston (Xarelto/rivaroxaban), In re Copaxone 40 mg, and Ferring v. Barr (DDAVP), plus the RNAi trade-secret case Alnylam v. Dicerna. I could not verify specific verdicts or Federal Circuit outcomes attributable to him from the sources reviewed, so no results are asserted here. He does appear in PTAB proceedings: his firm describes substantial IPR/patent-office trial experience, he is listed on a 2014 IPR power of attorney in Senju Pharmaceutical-related IPR2014-01043 (as Duane Morris counsel), and the Albaugh matter includes PGR2026-00026, filed February 20, 2026, challenging BASF's U.S. Patent 12,305,206 on L-glufosinate formulations. Bar admissions: District of Columbia (1999), Massachusetts (2013), U.S. Patent and Trademark Office, and the U.S. Court of Appeals for the Federal Circuit; J.D., University of Akron (1999).